DUBAI, UAE, Dec. 9, 2025 /PRNewswire/ — Bybit, the world’s second-largest cryptocurrency exchange by trading volume, is pleased to announce Boost Battle, a new competitive trading fiesta designed for wealth builders. Top-performing participants stand to win up to 10,000 USDT weekly, with competitions resetting each week.

Starting now until February 1, 2026, Boost Battle features eight weekly rounds where traders compete for prizes based on their trading volume. Each week, the highest ranking trader by accumulated points will win the grand prize of 10,000 USDT. To accept the challenge, eligible users may register now for the event and simply start trading to accumulate points. No complicated rules, no extra requirements – just trading.

How it works:

• Trading non-zero-fee pairs on Bybit Spot or Futures to accumulate points based on weekly trading volume
• In each round, registered participants can find the week’s featured “boosted tokens” on the event page for extra points
• Competing for the top position on the weekly leaderboard

Bonus Opportunity:

• Traders who achieve 10,000 USDT in daily trading volume on Spot or Futures will receive Lucky Draw tickets for additional prizes

Boost Battle is part of Bybit’s ongoing commitment to empowering traders at every experience level. By rewarding consistent trading activity and turning portfolio management into competitive opportunities, the event helps participants build momentum in their journey toward financial goals while making every trade count.

Restrictions apply. Full terms and conditions are available at: Boost Battle: Trade daily and win up to 10,000 USDT every week!

#Bybit / #TheCryptoArk / #IMakeIt

About Bybit

Bybit is the world’s second-largest cryptocurrency exchange by trading volume, serving a global community of over 70 million users. Founded in 2018, Bybit is redefining openness in the decentralized world by creating a simpler, open and equal ecosystem for everyone. With a strong focus on Web3, Bybit partners strategically with leading blockchain protocols to provide robust infrastructure and drive on-chain innovation. Renowned for its secure custody, diverse marketplaces, intuitive user experience, and advanced blockchain tools, Bybit bridges the gap between TradFi and DeFi, empowering builders, creators, and enthusiasts to unlock the full potential of Web3. Discover the future of decentralized finance at Bybit.com.

For more details about Bybit, please visit Bybit Press 

For media inquiries, please contact: media@bybit.com

For updates, please follow: Bybit’s Communities and Social Media

Discord | Facebook | Instagram | LinkedIn | Reddit | Telegram | TikTok | X | Youtube

In the news release, Empyrion Digital Unveils Johor’s Newest Large-scale Next-Generation Hyperscale Data Centre Campus, issued 08-Dec-2025 by Empyrion Digital over PR Newswire, we are advised by the company that the second paragraph, 1st sentence, should read “Malaysia’s recent tightening of approvals” rather than “Malaysia’s national data centre moratorium” as originally issued inadvertently; The second bullet point should read “One of Johor’s rare, approved DC sites”. The complete, corrected release follows:

Empyrion Digital Unveils Johor’s Newest Large-scale Next-Generation Hyperscale Data Centre Campus

• 200+MW hyperscale campus with five 40MW buildings
• One of Johor’s rare, approved DC sites
• Earliest energisation from Sep 2026; first phase targeted RFS in Q4 2026

SINGAPORE, Dec. 9, 2025 /PRNewswire/ — Empyrion Digital, a Singapore-headquartered next-generation data centre developer and operator, today announced regulatory approval for both the Electricity Supply Agreement (ESA) and Data Centre Task Force (DCTF) application for its first data centre campus in Malaysia. Located in Nusajaya within the SiLC Industrial Cluster of Johor, the project represents Empyrion Digital’s largest investment to date and its sixth data centre development across Asia.

The Johor Data Centre Campus (“MY1”) will be developed on a rare 34.9-acre site, making it one of the few projects in the country to secure both site approval and power allocation despite Malaysia’s recent tightening of approvals. This strategic milestone underscores the importance of MY1 not only to Johor’s digital infrastructure roadmap but also to the region’s accelerating AI and cloud computing ecosystem.

Designed as a 200+MW next generation hyperscale campus, MY1 will comprise five 40MW buildings developed in phases to meet surging demand for high-performance computing, artificial intelligence (AI), and cloud infrastructure in Southeast Asia. The first phase is targeted to be Ready-for-Service (RFS) in Q4 2026.

Empyrion Digital has secured 145MW of initial power allocation from Tenaga Nasional Berhad (TNB), with earliest energisation targeted for September 2026, and scalability to support the full campus. TNB will supply a stable, high-capacity electricity feed for hyperscale workloads.

MY1 will incorporate state-of-the-art liquid and air-cooled technologies, targeting a PUE below 1.3 for liquid cooling and below 1.4 for air cooling. The campus will also have access to green energy through long-term PPAs, in line with Empyrion Digital’s commitment to efficient and responsible operations.

Strengthening Cross-Border Connectivity Between Johor and Singapore

Beyond hyperscale capacity, MY1 will play a critical regional role in enhancing cross-border digital connectivity between Johor and Singapore. Through Empyrion’s sister connectivity platform, SPTel under Seraya Partners’ AQX Digital Infrastructure, customers will gain future access to secure, diverse, and low-latency routes linking MY1 in Johor to Empyrion’s SG1 data centre in Singapore.

These routes will significantly improve network diversity, operational resilience, and digital sovereignty, enabling customers to deploy multi-site AI, hybrid cloud, and disaster recovery architectures across the two locations. MY1 will therefore serve not only as a key hyperscale hub but also as a strategic extension of Singapore’s digital ecosystem.

Ernest Lee, Acting CEO of SPTel, said:
“We see strong potential in collaborating with Empyrion to integrate resilient connectivity and edge cloud capabilities across Singapore and Johor. By combining SPTel’s secure, software-defined network with Empyrion’s data centre footprint, we aim to deliver faster, more flexible digital infrastructure solutions for customers in the region.”

Mark Fong, CEO of Empyrion Digital, said:
“Malaysia has emerged as a key destination for hyperscale data centres, driven by strong digital transformation, favourable infrastructure, and government support. MY1 reflects Empyrion Digital’s continued ambition to expand our pan-Asian platform and meet our customers’ needs for scalable, green-by-design, and AI-ready infrastructure. Johor will be a cornerstone location in this strategy.”

Once completed, MY1 will join Empyrion Digital’s growing regional platform, which includes operational and development projects in Singapore, Seoul, Tokyo, Taipei, and Bangkok, bringing the company’s total IT capacity across Asia to well over 200MW.

About Empyrion Digital
Empyrion Digital is a next-generation digital infrastructure platform committed to sustainable practices and operational excellence. Green-by-design, we develop and operate scalable, carrier-neutral data centres for hyperscale and enterprise customers across Asia.

Headquartered in Singapore, Empyrion Digital is a portfolio company of Seraya Partners, a leading Asia infrastructure fund with USD 2.2 billion of assets under management as of 30 Sep 2025.

For more information, visit www.empyriondigital.com

VICTORIA, Seychelles, Dec. 9, 2025 /PRNewswire/ — MEXC, the fastest-growing global cryptocurrency exchange, redefining a user-first approach to digital assets through true zero-fee trading, has published its latest independent Proof of Reserves (PoR) report conducted by blockchain security and audit firm Hacken. MEXC continues to safeguard core assets while providing a fully auditable view of user balances, reinforcing our unwavering commitment to 100% fully backed user fund safety. The report, completed on November 26, 2025, confirms that MEXC holds sufficient on-chain assets to fully cover all user liabilities, with coverage ratios for major assets — including BTC, ETH, USDT, and USDC — consistently exceeding 100%.

According to the audit, Hacken conducted a comprehensive evaluation of MEXC’s reserves using industry-standard methodologies, including Proof of Liabilities, Proof of Ownership, reserve sufficiency calculations, and Merkle-tree verification. MEXC’s Proof of Reserves framework aggregates anonymized user balances and maps them to publicly verifiable on-chain holdings, enabling independent validation of solvency without compromising personal information. The auditor verified that MEXC maintains operational control over all wallets included in the assessment and confirmed that user balances are fully backed based on the assets reviewed.

The examination covered a broad range of networks, with reserve wallets identified across Bitcoin, Ethereum, Solana, TON, Tron, BNB Chain, Arbitrum, Optimism, Avalanche-C, Base, Polygon, Aptos and Sui. The report also provides detailed breakdowns of wallet addresses, balances, and asset distribution. The final reserve ratio table confirms that each major asset class is supported by reserves exceeding its liabilities.

Hacken reviewed outbound transactions from selected addresses as part of its Proof of Ownership procedures and validated the integrity of the Merkle-tree structure used to compute user liabilities. These transparency efforts are underpinned by MEXC’s continuously refreshed Proof of Reserves framework and an independently maintained protection system, giving users and counterparties verified confirmation of reserve coverage, strict asset segregation, and real-time fund accessibility.

“At MEXC, we are fully committed to transparency and security, and this report once again demonstrates our unwavering dedication to 100% user fund safety,” said Vugar Usi, COO of MEXC. “Independent Proof of Reserves audits are now a continuous, core standard practice within our operational framework. We will continue working with established auditing firms such as Hacken to ensure our users have verifiable assurance that their assets are fully backed.”

Hacken concludes that MEXC’s reserve structure demonstrates full solvency, including the accounting of off-exchange obligations. The report highlights the proper implementation of the PoR methodology, the quality of the supplied data, diversified asset holdings, and the exchange’s high level of responsibility toward its users.

“We’ve seen increased transparency demand in the crypto industry over the past year, and the results of MEXC’s audit reflect this shift”, noted a spokesperson for Hacken. “Our audit confirmed that the exchange has sufficient asset reserves and a clear reserve management structure. In an environment where trust is built only through verifiable data, MEXC demonstrates its willingness to operate transparently and back up its commitments with facts, not words”.

Hacken also emphasizes that the results serve as a “testament to the responsible financial management practices employed by MEXC, as well as the company’s dedication to transparency and accountability”.

Regular Proof of Reserves audits remain central to MEXC’s long-term strategy to strengthen trust and elevate industry standards. As global demand for accountability and compliance in cryptocurrency trading grows, verified reserve transparency has become essential to build user confidence and demonstrate real financial resilience. The release of the latest independent audit by Hacken powerfully reinforces MEXC’s standing as a global benchmark for trust, transparency, and resilience—setting a gold standard for accountability in the worldwide crypto ecosystem.

About MEXC

Founded in 2018, MEXC is committed to being “Your Easiest Way to Crypto.” Serving over 40 million users across 170+ countries, MEXC is known for its broad selection of trending tokens, everyday airdrop opportunities, and low trading fees. Our user-friendly platform is designed to support both new traders and experienced investors, offering secure and efficient access to digital assets. MEXC prioritizes simplicity and innovation, making crypto trading more accessible and rewarding.
MEXC Official Website｜ X ｜ Telegram ｜How to Sign Up on MEXC

About Hacken

Hacken is a trusted blockchain security auditor on a mission to make Web3 a safer place. With a team of 60+ certified engineers, it provides solutions covering all aspects of blockchain security, such as smart contract & protocol audits, bug bounties, and security assessments. Hacken has been raising the bar for blockchain security, working with more than 1,500 Web3 projects since its inception in 2017.
For more information, visit: Hacken Website｜X｜LinkedIn

SHANGHAI, Dec. 9, 2025 /PRNewswire/ — Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for cancer and immunological diseases, announced new data from its hematology portfolio at the 67th American Society of Hematology (ASH) Annual Meeting. Highlights include golidocitinib, a Janus kinase 1 (JAK1) only inhibitor, in T-cell lymphoma, and birelentinib, a non-covalent LYN/BTK dual inhibitor, in B-cell lymphoma.

Golidocitinib

• Newly diagnosed PTCL

Two dose regimes of golidocitinib combined with CHOP have been explored for the treatment of newly diagnosed PTCL. Both demonstrated promising antitumor activities and a manageable safety profiles.

• • Golidocitinib 75mg daily with CHOP, followed by 150mg maintenance after CHOP, showed an ORR of 94.1% and a CR rate of 64.7%. By the data cutoff date, 85% of patients remained on treatment.
  • Golidocitinib 150mg daily with CHOP, followed by 150mg maintenance after CHOP, showed an ORR of 88.9% and a CR rate of 61.1%
     
• R/R PTCL

An updated 2-year follow-up from the MD Anderson Cancer Center cohort of the multinational pivotal trial JACKPOT8 Part B showed that golidocitinib monotherapy in patients with relapsed or refractory peripheral T-cell lymphoma (r/r PTCL) achieved an objective response rate (ORR) of 53.8% and a complete response (CR) rate of 46.1%. Median progression-free survival (PFS) was 37.9 months and the 2-year PFS rate was 58.3%. The research findings validated golidocitinib’s long-lasting efficacy and tolerability in the U.S. patient population.

• Rare subtypes of PTCL

Golidocitinib monotherapy demonstrated compelling clinical activity with a favorable safety profile in heavily pretreated relapsed or refractory T-cell and NK-cell large granular lymphocyte leukemia (r/r T-LGLL) patients. Results from a prospective study showed an ORR of 92.3% and a CR rate of 61.15%. Additionally, the study reported a 100% response among STAT3-wildtype patients.

A Phase II clinical study showed that golidocitinib in combination with CHOP demonstrated profound antitumor activity in treatment-naïve monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL). The ORR was 85.7% and the CR rate was 71.4%, demonstrating a significant therapeutic advance over conventional chemotherapy.

• PTCL-associated HLH

In r/r PTCL-associated hemophagocytic lymphohistiocytosis (HLH), golidocitinib-based regimens demonstrated dual anti-HLH and antitumor efficacy, with rapid clinical improvement and an ORR of 46.7%. Most patients achieved systemic and hematologic recovery with a manageable safety profile. These findings highlight the potential of JAK1 inhibition in this high-risk disease.

Birelentinib

Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is a malignancy originating from mature B-cell non-Hodgkin lymphoma (B-NHL). While Bruton’s tyrosine kinase (BTK) inhibitors have transformed the treatment of B-cell lymphomas, resistance remains a significant challenge. Two primary types of resistance mutations have been identified after BTK inhibitor treatment for B-NHL: BTK-dependent and non-BTK pathway-mediated resistance. Although the BTK-dependent resistance is well-characterized, the emergence of kinase-impaired BTK mutations underscores the increasingly recognized role of non-BTK pathways.

Birelentinib is designed to block both BTK-dependent and BTK independent BCR signaling. Building upon promising data presented orally at the 2025 ASCO Annual Meeting and the 18th International Conference on Malignant Lymphoma (ICML), updated follow-up data of birelentinib reported at this ASH Annual Meeting demonstrated potent anti-tumor efficacy with a manageable safety profile in heavily pre-treated CLL/SLL patients.

At 50 mg QD (RP3D), birelentinib achieved an ORR of 84.2%. Tumor responses were observed irrespective of prior BTK inhibitor, BCL-2 inhibitor or BTK degrader treatment, and in patients with kinase-proficient or kinase-impaired BTK mutation. Antitumor efficacy proved durable, with no new safety concerns identified during follow-up.

Based on the encouraging results, birelentinib has received Fast Track Designation (FTD) from the U.S. Food and Drug Administration (FDA). The global multicenter Phase III study in r/r CLL/SLL is currently ongoing.

About Golidocitinib (DZD4205)

Golidocitinib is currently the first and only Janus kinase 1 (JAK1) inhibitor being evaluated for the treatment of r/r PTCL. In June 2024, golidocitinib was approved by the National Medical Products Administration (NMPA) of China for the treatment of adult patients with relapsed or refractory peripheral T-cell lymphoma (r/r PTCL).

At the data cut-off date of August 31, 2023, golidocitinib has demonstrated robust and durable anti-tumor efficacy, with an ORR of 44.3%. All subtypes benefited well, and the ORR of common subtypes exceeded 40%. More than 50% of the patients with tumor remission achieved a complete response with a CRR of 23.9%. Per IRC assessment, the median duration of response (mDoR) reached 20.7 months. As of February 2024, golidocitinib showed a median overall survival (mOS) of 24.3 months.

Golidocitinib was granted Fast Track Designation by the U.S. FDA for the treatment of r/r PTCL in February 2022. In September 2023, the CDE accepted its NDA and granted Priority Review for the treatment of r/r PTCL. The Phase I clinical data of golidocitinib (JACKPOT8 PART A) were published in Annals of Oncology (Impact Factor: 51.8), and global pivotal trial data of golidocitinib for the treatment of r/r PTCL (JACKPOT PART B) were published in The Lancet Oncology (Impact Factor: 54.4).

About Birelentinib (DZD8586)

Two resistance mechanisms have been found in patients whose diseases have progressed on a BTK inhibitor treatment: the BTK C481X mutation and BTK-independent BCR signaling pathway activation. Birelentinib is a first-in-class, non-covalent, LYN/BTK dual inhibitor with full blood-brain barrier (BBB) penetration, designed to treat both BTK-dependent and BTK-independent B-cell non-Hodgkin lymphoma (B-NHL).

In August 2025, birelentinib was granted Fast Track Designation by the U.S. FDA for the treatment of adult patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.

About Dizal

Dizal is a biopharmaceutical company, dedicated to the discovery, development and commercialization of differentiated therapeutics for the treatment of cancer and immunological diseases worldwide. Deep-rooted in translational science and molecular design, it has established an internationally competitive portfolio. ZEGFROVY is the first and only small molecule drug approved in both the U.S. and China, for the treatment of non-small cell lung cancer with EGFR exon20 insertion mutations. Golidocitinib has been approved in China for the treatment of relapsed and refractory PTCL. To learn more about Dizal, please visit www.dizalpharma.com, or follow us on Linkedin or X.

Forward-Looking Statements

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words “anticipate”, “believe”, “estimate”, “expect”, and “intend” and similar expressions, as they relate to Dizal, are intended to identify certain forward-looking statements. Dizal does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections, and understandings of the management of Dizal with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties, and other factors, some of which are beyond Dizal’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Dizal’s competitive environment, and political, economic, legal, and social conditions.

Dizal, the Directors, and the employees of Dizal assume (a) no obligation to correct or update the forward-looking statements contained on this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turnout to be incorrect.

Contacts
Investor Relations: ir@dizalpharma.com
Business Development: bd@dizalpharma.com
Media Contact: pr@dizalpharma.com

ADELAIDE, Australia, Dec. 9, 2025 /PRNewswire/ — Sungrow, the leading global PV inverter and energy storage system provider, marked the official commencement of construction of client ENGIE’s Pelican Point BESS at Pelican Point Power Station, together delivery partners Elecnor and Electranet. This landmark utility-scale project is designed to further strengthen South Australia’s renewable-rich power grid.

Situated next to the Pelican Point Power Station in Outer Harbour, Adelaide, the 200 MW / 400 MWh BESS is currently in development and is expected to begin operation in the second half of 2027. South Australia already leads the world in renewable energy penetration, but the state’s rapid shift to wind and solar has also introduced new operational challenges, including increasing system strength risks, frequency volatility, and the need for fast-response capacity during periods of high renewable output and low synchronous generation. The Pelican Point BESS is designed to effectively address these challenges by providing large-scale storage, grid stability services, and improved system resilience for the wider network. Once completed, the system will have the capacity to store and discharge enough to power more than 29,400 average South Australian Homes.

• First Grid-Forming BESS to Support South Australia’s Clean Energy Transition

South Australia continues to lead the nation in renewable energy adoption, but high penetration of solar and wind generation brings challenges for grid stability and reliability. The Pelican Point BESS is designed to manage this variability and maintain grid strength during periods of peak renewable output. The project also demonstrates how existing energy infrastructure can be modernised and repurposed to support the evolving needs of a decarbonised power system which is an important milestone for both ENGIE and Sungrow.

For Sungrow, Pelican Point is the company’s first grid-forming BESS project in South Australia. It showcases advanced technical capabilities needed to maintain system strength under high renewable penetration. Located next to the Pelican Point Power Station, the project uses a complementary hybrid operational model where the upgraded gas plant and the new battery system work together to support flexible and reliable energy delivery.

• Technical Highlights: PowerTitan 2.0 and Grid-Forming Innovation

The project will deploy a suite of integrated Sungrow technologies engineered for utility-scale performance and reliability, including:

• • Grid-Forming Capability for Superior Support: An integrated skid with inverters, MV transformers and RMU, delivering advanced bidirectional power conversion with grid-forming capability. The SC6900UD-MV Power Conversion System (PCS) inverters are well-suited for utility-scale applications, supporting robust grid services and high efficiency.
  • Pre-Integrated solution for Long-Term Value: Featuring high energy density, liquid cooling, and advanced battery management, the ST5015UX Battery Containers from the PowerTitan 2.0 Series ensure reliability, safety, and a long cycle life. These pre-assembled, factory-tested containers enable accelerated onsite installation and minimize system integration risk.
  • Agile-Dispatching for Market and Grid Requirements: The PPC EMS3000 Plant Controller provides comprehensive plant control, monitoring, and grid integration services. The EMS is designed for scalable, utility-class storage plants and ensures the system can respond to market signals, grid stability requirements, and site-specific operational needs.

• Strengthening Australia’s Energy Future Through Partnership

ENGIE’s partnership with Sungrow highlights strong confidence in Sungrow’s global BESS expertise and technology leadership. Together, the partners will deliver the project to the highest standards of performance, safety, and operational excellence.

“The Pelican Point BESS marks an important step in Australia’s clean energy evolution. By combining Sungrow’s advanced grid-forming technology with ENGIE’s commitment to a carbon-neutral future, we’re delivering a solution built for today’s needs and tomorrow’s energy system. We’re proud to support South Australia as it continues to lead Australia in renewable integration.”  Joe Zhou, Country Director of Sungrow Australia stated.

With development underway and commissioning set for the second half of 2027, the Pelican Point BESS is poised to become a key asset in South Australia’s energy transition. Long term, it will enable deeper renewable integration, greater grid flexibility, and support future hybrid energy models.

About Sungrow

Sungrow, a global leader in renewable energy technology, has pioneered sustainable power solutions for over 28 years. As of June 2025, Sungrow has installed 870 GW of power electronic converters worldwide. The Company is recognized as the world’s most bankable PV inverter and energy storage company (BloombergNEF). Its innovations power clean energy projects across the globe, supported by a network of 520 service outlets guaranteeing excellent customer experience. At Sungrow, we’re committed to bridging to a sustainable future through cutting-edge technology and unparalleled service. For more information, please visit: www.sungrowpower.com/en.

About ENGIE

ENGIE is a major player in the energy transition, whose purpose is to accelerate the transition towards a carbon-neutral economy. With 98,000 employees in 30 countries, the Group covers the entire energy value chain, from production to infrastructures and sales. ENGIE combines complementary activities: renewable electricity and green gas production, flexibility assets (notably batteries), gas and electricity transmission and distribution networks, local energy infrastructures (heating and cooling networks) and the supply of energy to individuals, local authorities and businesses. Every year, ENGIE invests more than €10 billion to drive forward the energy transition and achieve its net-zero carbon goal by 2045.

Media Contact:

Luly Wang
luly.wang@sungrow-hq.com 

INNSBRUCK, Austria, Dec. 9, 2025 /PRNewswire/ — As cyberattacks continue to challenge even the most resilient organisations, the need for clear, trustworthy, and openly documented security testing has never been more critical. AV-Comparatives, renowned for its independent and methodology-driven evaluations, reaffirms this importance by spotlighting the findings of its 2025 Endpoint Prevention and Response (EPR) Test and EDR Detection Validation Test.

These two enterprise-focused reports demonstrate that in a landscape filled with marketing claims, technical jargon, and complex product offerings, what organisations need most is transparent, comparable, and easy-to-understand insight into how security solutions perform under real-world conditions.

Transparency: The Foundation of Trust

The full methodology, scenarios, scoring, and per-step attack analyses for both tests are publicly available. The EPR Test can be accessed at:
https://www.av-comparatives.org/tests/endpoint-prevention-response-epr-test-2025/

The EDR Detection Validation Test is available at:
https://www.av-comparatives.org/news/edr-detection-validation-2025/

By openly publishing these details, AV-Comparatives provides enterprises with complete visibility and transparency into how products were evaluated and why certain results were achieved. This openness ensures that security leaders, analysts, and technical teams can independently interpret the findings without relying on opaque summaries or selective reporting.

Comparability: Making Enterprise Decisions Practical

One of the greatest challenges facing CISOs and SOC leaders is the difficulty of comparing endpoint security products fairly. Many evaluations lack consistent standards or isolate techniques from real intrusion context.

AV-Comparatives addresses this by conducting full kill-chain attack simulations applied uniformly across all solutions, based on the MITRE ATT&CK framework. Every vendor faces the same adversary sequence, the same operational constraints, and the same scoring model. The result is a truly comparative view that helps organisations understand not just whether a technique was detected, but how each product performs throughout a realistic attack scenario.

This comparability is essential for selecting, deploying, and continuously improving enterprise defence strategies.

Reliability: Independent, Consistent, and Real-World Focused

The EPR Test 2025 evaluated 50 multi-stage attacks covering initial compromise through lateral movement, credential theft, command and control, exfiltration, and impact. Active blocking and passive detection modes were assessed alongside operational accuracy and five-year cost modelling for a 5,000-endpoint environment.

The EDR Detection Validation Test 2025 examined visibility and detection quality with prevention disabled, assessing whether SOC teams would receive coherent, actionable telemetry during all phases of a complex intrusion. Seven leading enterprise solutions participated, with five meeting the certification requirements.

Participants included all major players, such as Bitdefender, Check Point, CrowdStrike, Elastic, ESET, Fortinet, G DATA, Kaspersky, Palo Alto Networks, VIPRE, and two anonymous vendors who failed to reach the certification.

Across both reports, the emphasis remains consistent: real threats, realistic sequences, real results. This reliability is why AV-Comparatives continues to be referenced by enterprises, analysts, research institutions, and global media.

Clarity: Turning Complex Attacks Into Understandable Insights

Even the most accurate technical findings lose value if they are not communicated clearly. AV-Comparatives’ reports are structured to be informative not only for analysts but also for executives responsible for cybersecurity investment and risk management.

Each test includes step-by-step attack flows, product reactions, and final summaries crafted to support informed decision-making. This clarity helps organisations bridge the gap between technical detail and strategic action – a critical need in modern cybersecurity operations.

Designed for the Global Cybersecurity Community

With more than two decades of independent testing experience, AV-Comparatives remains committed to producing meaningful, openly documented evaluations. The 2025 reports reflect that mission: a commitment to providing the global cybersecurity community with accurate, comprehensible, and comparable results.

Enterprises require more than partial snapshots or isolated detections. They need full-context testing that mirrors the realities of today’s threat landscape. AV-Comparatives continues to deliver exactly that, year after year, across EDR, EPR, endpoint protection, and other enterprise-focused evaluations.

A Message from Andreas Clementi, CEO of AV-Comparatives:

“Security leaders face enormous pressure to choose the right technologies in an environment saturated with complexity. Transparency, comparability, and clarity are essential. Our 2025 enterprise reports demonstrate our commitment to providing openly documented, realistic tests that help organisations understand how solutions behave in practice, not just in theory.”

About AV-Comparatives

AV-Comparatives is an independent cybersecurity testing lab founded in 2004. Known for transparent methodologies and real-world testing, the organisation provides certification programs and comprehensive assessments for both consumer and enterprise security products.